Drug Trial Radar · NCT07206056
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
188
Planned (sponsor's estimate)
Start
Oct 15, 2025
Primary completion
Nov 9, 2029
Study completion Dec 1, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).
Conditions
- Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions
Tulmimetostat DL1 QDDrug
Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))
Tulmimetostat DL2 QDDrug
Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))
Tulmimetostat DL3 QDDrug
Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))
Tulmimetostat Doses 1 or 2 QDDrug
Part 1b (dose expansion and optimization): tulmimetostat doses 1 or 2 QD
Tulmimetostat RP2D QDDrug
Part 2: tulmimetostat Recommended Phase 2 Dose (RP2D) QD
JSB462 Dose 1 QDDrug
JSB462 Dose 1 QD
JSB462 Dose 2 QDDrug
JSB462 Dose 2 QD
JSB462 QDDrug
The dose of JSB462 QD will be determined based on the totality of data from Part 1a
Standard of Care (SoC)Drug
Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1a: Dose-limiting toxicities (DLTs)Time frame: Up to 28 days
- Part 1a and Part 1b: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 14 months
- Part 1a and Part 1b: Number of Participants with dose adjustmentsTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 14 months
- Part 1a and Part 1b: Dose IntensityTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 14 months
- Part 1a and Part 1b: Duration of exposure to each study drugTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 14 months
- Part 1b and Part 2: prostate-specific antigen 50 (PSA50) at Month 6Time frame: Month 6
Locations
35 sites in 14 countries. Site status is shown where the registry gives one.
Sarah Cannon Research Institute
Denver, Colorado · Recruiting
Sarah Cannon Research Institute
Jacksonville, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Wichita Urology Group PA
Wichita, Kansas · Recruiting
Mass General Hospital
Boston, Massachusetts · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Novartis Investigative Site
Liverpool, Australia · Recruiting
Novartis Investigative Site
St Leonards, New South Wales, Australia · Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia · Recruiting
Novartis Investigative Site
Halifax, Nova Scotia, Canada · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Herlev, Denmark · Recruiting
Novartis Investigative Site
Odense C, Denmark · Recruiting
Novartis Investigative Site
Vejle, Denmark · Recruiting
Novartis Investigative Site
Bordeaux, France · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, Germany · Recruiting
Novartis Investigative Site
Jena, Thuringia, Germany · Recruiting
Novartis Investigative Site
Milan, MI, Italy · Recruiting
Novartis Investigative Site
Padova, PD, Italy · Recruiting
Novartis Investigative Site
Orbassano, TO, Italy · Recruiting
Novartis Investigative Site
Kuching, Sarawak, Malaysia · Recruiting
Novartis Investigative Site
Tlalpan, Mexico City, Mexico · Recruiting
Novartis Investigative Site
Poznan, Poland · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Santiago Compostela, A Coruna, Spain · Recruiting
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
Novartis Investigative Site
London, United Kingdom · Recruiting
Novartis Investigative Site
Sutton, Surrey, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.